High-ranking FDA official suddenly retiring casts a shadow over cancer drug policies.

Richard Pazdur, senior drug regulation official at the Food and Drug Administration (FDA) suddenly retired, raising questions about the timing and prioritization of cancer drug reviews. Analysts say big pharmaceutical companies like Merck will be affected by this event.